



# Cytomegalovirus in the Transplantation Setting

Assessing the Evidence  
in Real-world Applications

**Friday, October 23, 2020**  
**7:00 PM – 8:30 PM ET**  
**Virtual Satellite Symposium**  
with **LIVE Question and Answer**  
held during **IDWeek™ 2020**

## ACTIVITY CHAIR

**Francisco M. Marty, MD, FIDSA**

## FACULTY

**Roy F. Chemaly, MD, MPH, FIDSA, FACP**  
**Genovefa A. Papanicolaou, MD, FIDSA**

This continuing medical education activity is provided by



This activity is supported by an educational grant  
from Merck & Co., Inc.

This activity is not affiliated with the official  
program of **IDWeek™ 2020**.

## OVERVIEW

In this CME webinar, expert clinicians will discuss incorporating recent evidence into practice regarding the use of prophylactic and preemptive measures for cytomegalovirus (CMV) disease. They will compare conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients. They will also evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

## LEARNING OBJECTIVES

Upon successful completion of this activity, participants should be better able to:

- Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent CMV disease in transplant recipients.
- Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients.
- Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

## TARGET AUDIENCE

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with CMV.

## AGENDA

### Introduction

*Francisco M. Marty, MD, FIDSA*

### CMV in the Transplant Setting: An Ongoing Dilemma

*Genovefa A. Papanicolaou, MD, FIDSA*

### CMV Mitigation: Current Status

*Roy F. Chemaly, MD, MPH, FIDSA, FACP*

### Case Discussion: Secondary CMV Prophylaxis in HSCT Patient Who Experienced Adverse Effects From Anti-CMV Antivirals

*Roy F. Chemaly, MD, MPH, FIDSA, FACP*

### CMV: Controversies in Management

*Francisco M. Marty, MD, FIDSA*

### Case Discussion: Solid Organ Transplant Patient With CMV Reactivation

*Genovefa A. Papanicolaou, MD, FIDSA*

## LIVE Question and Answer

### ACTIVITY CHAIR



#### **Francisco M. Marty, MD, FIDSA**

Associate Professor of Medicine  
Harvard Medical School  
Associate Physician, Brigham and Women's Hospital  
Staff Physician, Dana-Farber Cancer Institute  
*Boston, MA*

### FACULTY



#### **Roy F. Chemaly, MD, MPH, FIDSA, FACP**

Professor of Medicine  
Director, Clinical Virology Research  
Director, Infection Control Section  
Department of ID/IC/EH  
UT MD Anderson Cancer Center  
Professor, Division of Epidemiology,  
Human Genetics, and Environmental Sciences  
UT School of Public Health  
Adjunct-Professor of Medicine  
Baylor College of Medicine  
*Houston, TX*



#### **Genovefa A. Papanicolaou, MD, FIDSA**

Attending Physician, Infectious Disease Service  
Memorial Sloan Kettering Cancer Center  
*New York, NY*



Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 1.50 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support, all planners, teachers, and authors involved in the development of accredited content are required to disclose to the accredited provider their **relevant financial relationships**. Relevant financial relationships will be mitigated and disclosed to the activity audience.

Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from the Program Director and the Office of Medical Affairs and Compliance.

*You're invited...*

- What: **Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications**
- When: **Friday, October 23, 2020**  
7:00 PM – 8:30 PM ET  
Virtual Satellite Symposium With  
LIVE Question and Answer
- Why: Earn up to **1.50** CME credits
- How: Access within the Affiliated  
Event Theater on the **IDWeek™**  
2020 Virtual Platform



6900 Grove Road • Building 100  
Thorofare, NJ 08086-9447

Presorted  
First Class Mail  
US Postage  
PAID  
Permit # 906  
Bellmawr NJ

